Schizophrenia - Current and Future Players

  • ID: 4032660
  • Report
  • 114 pages
  • GlobalData
1 of 4

FEATURED COMPANIES

  • Alkermes
  • Dainippon Sumitomo
  • Eli Lilly
  • Intra-Cellular Therapies
  • Janssen
  • Lundbeck
  • MORE
Schizophrenia - Current and Future Players

Summary

The author has released their pharma report, “Schizophrenia - Current and Future Players”. The report is a vital source of up-to-date information with in-depth analysis on the companies in the rapidly growing Schizophrenia Market. The report identifies and analyses the key companies shaping and driving the global Schizophrenia market. The report provides insight into the competitive Schizophrenia landscape, including new companies entering the market. This report is built using data and information sourced from proprietary databases, primary and secondary and in-house analysis by a team of industry experts.

Scope

- Investigation of current and future market competition for Schizophrenia
- Competitor assessment
- Coverage of key market players and company profiles including business description, financial overview and SWOT analysis.
- Strategic assessment of Schizophrenia sector through market impact analysis, future market scenario and company analysis

Reasons to buy

- Gain a high level view of the trends shaping and driving Schizophrenia market
- Assess competitiveness of products in market by understanding the strengths and weaknesses of current competition.
- Create an effective counter-strategy to gain a competitive advantage against those currently in the market
- What’s the next big thing in the global Schizophrenia market landscape? Identify, understand and capitalize
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Alkermes
  • Dainippon Sumitomo
  • Eli Lilly
  • Intra-Cellular Therapies
  • Janssen
  • Lundbeck
  • MORE
1.1 List of Tables

1.2 List of Figures

2 Introduction

2.1 Catalyst

2.2 Related Reports

3 Market Outlook

3.1 Global Markets

3.1.1 Forecast

3.1.2 Drivers and Barriers - Global Issues

4 Current and Future Players

4.1 Overview

4.2 Trends in Corporate Strategy

4.3 Company Profiles

4.3.1 Alkermes

4.3.2 Dainippon Sumitomo

4.3.3 Eli Lilly

4.3.4 Intra-Cellular Therapies

4.3.5 Janssen

4.3.6 Lundbeck

4.3.7 Minerva Neurosciences

4.3.8 Otsuka

5 Appendix

5.1 Bibliography

5.2 Abbreviations

5.3 Methodology

5.4 Forecasting Methodology

5.4.1 Diagnosed Schizophrenia Patients

5.4.2 Percent Drug-Treated Patients

5.4.3 Launch and Patent Expiry Dates

5.4.4 General Pricing Assumptions

5.4.5 Individual Drug Assumptions

5.4.6 Generic Erosion

5.4.7 Pricing of Pipeline Agents

5.5 Primary Research - KOLs Interviewed for this Report

5.6 Primary Research - Prescriber Survey

5.7 About the Authors

5.7.1 Analyst

5.7.2 Therapy Area Director

5.7.3 Epidemiologist

5.7.4 Managing Epidemiologist

5.7.5 Global Director of Therapy Analysis and Epidemiology

5.8 About the Author

5.9 Disclaimer

1.1 List of Tables

Table 1: Schizophrenia Market - Drivers and Barriers, 2015-2025

Table 2: Key Companies in the Schizophrenia Market in the 7MM, 2015

Table 3: Alkermes’ Schizophrenia Portfolio Assessment, 2015

Table 4: Alkermes SWOT Analysis in Schizophrenia, 2015-2025

Table 5: Dainippon Sumitomo’s Schizophrenia Portfolio Assessment, 2015

Table 6: Dainippon Sumitomo SWOT Analysis in Schizophrenia, 2015-2025

Table 7: Eli Lilly’s Schizophrenia Portfolio Assessment, 2015

Table 8: Eli Lilly SWOT Analysis in Schizophrenia, 2015-2025

Table 9: Intra-Cellular Therapies’ Schizophrenia Portfolio Assessment, 2015

Table 10: Intra-Cellular Therapies SWOT Analysis in Schizophrenia, 2015-2025

Table 11: Janssen’s Schizophrenia Portfolio Assessment, 2015

Table 12: Janssen SWOT Analysis in Schizophrenia, 2015-2025

Table 13: Lundbeck’s Schizophrenia Portfolio Assessment, 2015

Table 14: Lundbeck SWOT Analysis in Schizophrenia, 2015-2025

Table 15: Minerva Neurosciences’ Schizophrenia Portfolio Assessment, 2015

Table 16: Minerva Neurosciences SWOT Analysis in Schizophrenia, 2015-2025

Table 17: Otsuka’s Schizophrenia Portfolio Assessment, 2015

Table 18: Otsuka SWOT Analysis in Schizophrenia, 2015-2025

Table 19: Key Launch Dates

Table 20: Key Patent/Exclusivity Expiries

Table 21: High-Prescribing Psychiatrists (Non-KOLs) Surveyed, By Country

1.2 List of Figures

Figure 1: Global Sales for Schizophrenia by Region, 2015-2025

Figure 2: Global Sales for Schizophrenia by Drug Class, 2015-2025

Figure 3: Global Sales of Products for Schizophrenia by Company, 2015-2025

Figure 4: Company Portfolio Gap Analysis in Schizophrenia, 2015-2025
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • Alkermes
  • Dainippon Sumitomo
  • Eli Lilly
  • Intra-Cellular Therapies
  • Janssen
  • Lundbeck
  • Minerva Neurosciences
  • Otsuka
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll